glaucoma: Increased pressure in the eyeball due to obstruction of the outflow of aqueous humor.
Endpoint definition
↥
Endpoint definition steps |
FinnGen |
|---|---|
Phenotype data |
473681 |
1. Apply sex-specific ruleNone |
473681 |
2. Check conditionsNone |
473681 |
3. Check pre-conditions, main-only, mode, registry filtersRegistry filters:
1 out of 7 registries used, show all original rules. |
2864 |
4. Check minimum number of events
Min. number of events
3
|
2864 |
5. Include endpointsNone |
2864 |
6. Filter based on genotype QC (FinnGen only) |
2737 |
Control definitions (FinnGen only)
Control exclude
H7_GLAUCOMA
Extra metadata
Level in the ICD hierarchy
3
First used in FinnGen datafreeze
DF2
Similar endpoints
↥List of similar endpoints to
Use of antiglaucoma preparations and miotics
based on the number of shared cases.
Similar with more cases:
- Glaucoma
- Diseases of the eye and adnexa
- Any event in hilmo or specialist outpatient
- Any prescribed medicine buy
Similar with less cases:
None
Case counts by codes
↥
Summary Statistics
↥-FinRegistry-
Key figures
| All | Female | Male | |
|---|---|---|---|
| Number of individuals | |||
| Whole population | 31315 | 19313 | 11757 |
| Only index persons | 26241 | 16426 | 9815 |
| Unadjusted period prevalence (%) | |||
| Whole population | 0.47 | 0.55 | 0.33 |
| Only index persons | 0.52 | 0.60 | 0.37 |
| Median age at first event (years) | |||
| Whole population | 71.87 | 73.07 | 69.86 |
| Only index persons | 70.67 | 71.97 | 68.49 |
-FinnGen-
Key figures
| All | Female | Male | |
|---|---|---|---|
| Number of individuals | 2737 | 1468 | 1269 |
| Unadjusted period prevalence (%) | 0.60 | 0.58 | 0.64 |
| Median age at first event (years) | 67.66 | 67.08 | 68.34 |
-FinRegistry-
Age distribution of first events
-FinnGen-
Age distribution of first events
-FinRegistry-
Year distribution of first events
-FinnGen-
Year distribution of first events
-FinRegistry-
Cumulative Incidence Function
-FinnGen-
Cumulative Incidence Function
Mortality – FinRegistry
↥Association
Association between endpoint H7_GLAUCOMAMEDICATION and mortality.
Females
| Parameter | HR [95% CI] | p-value |
|---|---|---|
| H7_GLAUCOMAMEDICATION | 0.897 [0.84, 0.96] | 0.002 |
| Birth year | 0.99 [0.98, 1.0] | 0.019 |
During the follow-up period (1.1.1998 — 31.12.2019), 5847 out of 15112 females with H7_GLAUCOMAMEDICATION died.
Males
| Parameter | HR [95% CI] | p-value |
|---|---|---|
| H7_GLAUCOMAMEDICATION | 0.969 [0.89, 1.06] | 0.483 |
| Birth year | 0.986 [0.98, 1.0] | 0.004 |
During the follow-up period (1.1.1998 — 31.12.2019), 3519 out of 9395 males with H7_GLAUCOMAMEDICATION died.
Mortality risk
Mortality risk for people of age
years, who have H7_GLAUCOMAMEDICATION.| N-year risk | Females | Males |
|---|---|---|
| 1 | 0.089% | 0.153% |
| 5 | 0.487% | 1.08% |
| 10 | 1.161% | 2.555% |
| 15 | 2.208% | 5.031% |
| 20 | 3.784% | 8.639% |
Relationships between endpoints
↥Index endpoint: H7_GLAUCOMAMEDICATION – Use of antiglaucoma preparations and miotics
GWS hits: 8
Endpoint
Case Overlap
Survival Analysis
Genetic Correlations
Genetic Signals
N (Jaccard index)
HR [CI]
Extremity
rg [CI]
Extremity
Hits
Coloc Hits
FinRegistry
FinnGen
FinRegistry
FinnGen
FinnGen
Loading data